MétaCan
Menu
Back to cohort
Record W4402560505 · doi:10.1016/j.drugpo.2024.104587

A call for compassionate opioid overdose response

2024· article· en· W4402560505 on OpenAlexaff
Erin Russell, Mary Hawk, Joanne Neale, Alex S. Bennett, Corey S. Davis, Lucas G. Hill, Rachel Winograd, Lauren Kestner, Amy Lieberman, Alice Bell, Tim Santamour, Stephen Murray, Kristin E. Schneider, Alexander Y. Walley, T. Stephen Jones

Bibliographic record

VenueInternational Journal of Drug Policy · 2024
Typearticle
Languageen
FieldMedicine
TopicOpioid Use Disorder Treatment
Canadian institutionsSt. Stephen's University
FundersJohns Hopkins Bloomberg School of Public HealthJohns Hopkins UniversityUniversity of PittsburghGraduate School of Public Health, University of PittsburghVital StrategiesBloomberg American Health Initiative
KeywordsOpioid overdoseOpioidDrug overdoseCompassionate UsePsychologyMedicineMedical emergencyPoison controlCriminology(+)-NaloxoneClinical trial

Abstract

fetched live from OpenAlex

• Standard dose naloxone is 0.4 mg intramuscular (IM) or ≤4 mg intranasal (IN). • high dose and long-acting opioid antagonists have no use in overdose response. • people who use drugs should be involved in opioid antagonist development. • harm reduction programs can teach rescue breathing to mitigate withdrawal risk. • withdrawal should be carefully considered in opioid antagonist product selection. High dose and long-acting opioid overdose reversal drugs can precipitate withdrawal in people who are opioid dependent. Products recently brought to market for community use in the United States (US) have drawn international concern because of their increased risk of withdrawal. At the March 18–19, 2024, Compassionate Overdose Response Summit & Naloxone Dosing Meeting, a panel of harm reduction experts issued the following call to action: 1) people who use drugs should be directly involved in decisions regarding the research, development, selection, and distribution of opioid overdose reversal products; 2) regulatory agencies and pharmaceutical manufacturers should carefully consider and communicate the risk and duration of withdrawal associated with higher dose and longer-acting opioid antagonists; 3) take-home naloxone kits should include at least two doses of an intramuscular (IM) product containing 0.4 mg or an intranasal (IN) product containing ≤4 mg; 4) At this time, high dose and long-acting opioid antagonists have no use in acute opioid overdose response; and, 5) overdose response educational materials, instructions on overdose response, and training should emphasize the restoration of breathing, avoiding withdrawal, and compassionate post-overdose support and care. High dose and long-acting opioid overdose reversal drugs were approved without testing for withdrawal and are often aggressively marketed despite decades of evidence from naloxone distribution programs worldwide that the ideal dose of naloxone is one that restores breathing without inducing withdrawal. Government agencies should direct resources to harm reduction programs to make standard dose take-home naloxone products widely available among people who use drugs. Lay bystanders, people who use drugs, their families, and professional first responders can learn and apply a compassionate approach to opioid overdose response.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.020
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.201
Threshold uncertainty score0.672

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0080.020
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0010.000
Science and technology studies0.0060.003
Scholarly communication0.0070.007
Open science0.0030.010
Research integrity0.0400.029
Insufficient payload (model declined to judge)0.2010.078

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.369
Teacher spread0.355 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations25
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueInternational Journal of Drug PolicySame topicOpioid Use Disorder TreatmentFrench-language works237,207